Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin in pediatric r/r sALCL or HL
NCT01492088Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2012
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of brentuximab vedotin in systemic anaplastic large cell lymphoma (sALCL) and Hodgkin lymphoma (HL) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 15 months, Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs up to 15 months and 5 more. Started Apr 2012; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
systemic anaplastic large cell lymphoma (sALCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01492088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01492088.